The risk of Endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials
The risk of Endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials
复制标题
DOI：
10.1016/j.ajo.2007.04.011
复制
发表时间：
2007-09-01
影响因子：
4.2
通讯作者：
Glassman, Adam R.
中科院分区：
文献类型：
--
作者：
Bhavsar, Abdhish R.;Michael, S. P.;Glassman, Adam R.
目的：报告使用标准化注射程序玻璃体内注射后眼内炎的发生率。设计：两项随机临床试验。方法：在糖尿病视网膜病变临床研究网络（DRCR net）和视网膜静脉闭塞的标准治疗与皮质类固醇（SCORE）临床试验中，将预充式注射器（Allergan, Inc ., Irvine, California， USA）非保存的玻璃体内注射曲安奈德。标准化注射程序不包括在注射前几天使用局部抗生素。结果：截至2006年12月31日，在糖尿病视网膜病变临床研究网络糖尿病黄斑水肿试验中进行了1,378次玻璃体内注射（538只眼），在标准护理vs；皮质类固醇治疗视网膜静脉阻塞。迄今为止，在2009次注射中有1例眼内炎（0.05%，95%可信区间为0.001%至0.277%）。结论：采用玻璃体内注射的标准化程序，无需在注射前几天开具抗生素预防处方，即可实现低眼内炎发生率。
PURPOSE: To report the incidence of endophthalmitis following intravitreal injection using a standardized injection procedure.DESIGN: Two randomized clinical trials.METHODS: Nonpreserved intravitreal triamcinolone acetonide in prefilled syringes (Allergan, Inc, Irvine, California, USA) was injected intravitreally in the Diabetic Retinopathy Clinical Research Network (DRCR net) and the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) clinical trials. The standardized injection procedure did not include the use of topical antibiotics during the days prior to the injection.RESULTS: As of December 31, 2006, 1,378 intravitreal injections (538 eyes) have been administered in the Diabetic Retinopathy Clinical Research Network Diabetic Macular Edema trial and 631 injections (301 eyes) in Standard Care vs; COrticosteroid for REtinal Vein Occlusion. There was one case of endophthalmitis in the 2,009 injections to date (0.05%, 95% confidence interval 0.001% to 0.277%).CONCLUSION: A low rate of endophthalmitis is achievable using a standardized procedure for intravitreal injection without prescribing antibiotic prophylaxis on the days prior to the injection.